Clinical Trial Update: Efficacy and Safety of Pirfenidone in Patient With Dermatomyositis Interstitial Lung Disease (Dm-ILD) [Phase 3]

View source ↗

Summary

Phase 3 trial investigating pirfenidone for efficacy and safety in dermatomyositis-associated interstitial lung disease is in progress with unspecified status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatomyositis Interstitial Lung Disease

Drugs mentioned

• PIRFENIDONE (pirfenidone)

Snippet

Sponsor: Beijing Continent Pharmaceutical Co, Ltd. | Conditions: Dermatomyositis Interstitial Lung Disease (Dm-ILD) | Phase 3 | Status: UNKNOWN